Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-α, and leukocyte arylsulfatase-A activity in patients with bladder cancer

Koçak, Hikmet; Öner-İyidoğan, Yıldız; Koçak, Taner; Öner, Pernur

doi:10.1016/j.clinbiochem.2004.02.005

Cited by 26 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports have shown that IL8 is increased in the urine of patients with bladder cancer (55)(56)(57). Our data suggest that urine IL8 concentrations warrant further investigation as a biomarker in tumors that are in direct contact with the urinary tract, including bladder and prostate cancer.…”

Section: Discussionmentioning

confidence: 82%

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed

Carranza-Rua

Alfaro

et al. 2014

Clinical Cancer Research

202

155

View full text Add to dashboard Cite

Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden.Experimental Design: IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples from 126 patients with cancer. We correlated IL8 serum levels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis.Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n ¼ 16), renal cell carcinoma (RCC; n ¼ 23), non-small cell lung cancer (NSCLC; n ¼ 21), or hepatocellular carcinoma (HCC; n ¼ 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n ¼ 16; RCC, n ¼ 23; HCC, n ¼ 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n ¼ 16) and immunomodulatory monoclonal antibodies (melanoma, n ¼ 8). IL8 concentrations in urine (n ¼ 18) were mainly elevated in tumors with direct contact with the urinary tract.Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer.

show abstract

Section: Discussionmentioning

confidence: 82%

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed

Carranza-Rua

Alfaro

et al. 2014

Clinical Cancer Research

202

155

View full text Add to dashboard Cite

show abstract

“…Based on the previous detection of IL-8 in bladder carcinoma cell lines, urinary IL-8 levels were measured in patients differing in disease origin and stage. Urinary IL-8 levels were typically higher in subjects with invasive than in those with low-stage cancer [61][62][63] . Urine CXCL8 levels in patients with non-Hodgkin's lymphoma corrected to creatinine concentration were significantly higher in comparison with controls.…”

Section: Urine (U)mentioning

confidence: 99%

Chemokines in tumor proximal fluids

Kotyza¹

2017

BIOMED PAP

View full text Add to dashboard Cite

Chemokines are chemotactic cytokines produced by leukocytes and other types of cells including tumor cells. Their action is determined by the expression of cognate receptors and subsequent signaling in target cells, followed by the modulation of cytoskeletal proteins and the induction of other responses. In tumors, chemokines produced by neoplastic/stroma cells control the leukocyte infiltrate influencing tumor growth and progression. Tumor cells also express functional chemokine receptors responding to chemokine signals, promoting cell survival, proliferation and metastasis formation. Chemokines may be detected in serum of cancer patients, but due to the paracrine nature of these molecules, more significant concentrations are found in the tumor adjacent, non-vascular fluids, collectively called tumor proximal fluids. This review summarizes the expression of CC and CXC chemokines in these fluids, namely in interstitial fluid, pleural, ascitic, and cyst fluids, but also in urine, saliva, cerebrospinal fluid, cervical secretions and bronchoalveolar lavage fluid. Most comparative clinical studies reveal increased chemokine levels in high-grade tumor proximal fluids rather than in low-grade tumors and benign conditions, indicating shorter survival periods. The data confirm peritumoral fluid chemokines as sensitive diagnostic and prognostic markers, as well as offer support for chemokines and their receptors as potential targets for antitumor therapy.

show abstract

“…Although considerable effort has been devoted to identifying a prognostic model of MIBC that can provide useful information about survival and treatment options at diagnosis (4)(5)(6)(7)(8), the ability to predict the course of disease progression for patients with bladder cancer remains a major clinical challenge. Thus, there is a critical need for methods that are capable of identifying patients with MIBC that are likely to experience disease progression or metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…Conventional histopathological parameters such as tumor stage or grade are generally viewed as prognostic factors, and numerous biomarkers have been investigated as prognostic indicators of MIBC (4)(5)(6)(7)(8). However, there are no reliable urinary, histological or stage/grading criteria that can predict disease progression or metastasis of MIBC adequately, or inform the choice of a more aggressive approach to therapy, for example, radical cystectomy.…”

Section: Introductionmentioning

confidence: 99%

A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer

Kim

Jeong

et al. 2011

Mol Med

View full text Add to dashboard Cite

There are no reliable criteria to handle disease progression of muscle invasive bladder cancer (MIBC), which strongly influences patient survival. Therefore, an accurate predicting method to identify progressive MIBC patients is greatly needed. The aim of this study was to identify a genetic signature associated with disease progression in MIBC. To address this issue, we analyzed three independent cohorts (a training set, test set 1 and test set 2) comprising a total of 128 MIBC patients. Microarray gene expression profiling, including gene network analysis, was performed in the training set to identify a gene expression signature associated with disease progression. The prognostic value of the signature was validated in test set 1 and test set 2 by microarray and real-time reverse transcriptase polymerase chain reaction (RT-PCR), respectively. The determination of gene expression patterns by microarray data analysis identified 1,320 genes associated with disease progression. Gene network analysis of the 1,320 genes suggested that IL1B, S100A8, S100A9 and EGFR were important mediators of MIBC progression. We validated this putative four-gene signature in two independent cohorts (log-rank test, P < 0.05 each, respectively) and estimated the predictive value of the signature by multivariate Cox regression analysis (hazard ratio [HR], 6.24; 95% confidence interval [CI], 1.58-24.61; P = 0.009). Finally, signature-based stratification demonstrated that the four-gene signature was an independent predictor of MIBC progression. In conclusion, a molecular signature defined by four genes represents a promising diagnostic tool for the identification of MIBC patients at high risk of progression.

show abstract

Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-α, and leukocyte arylsulfatase-A activity in patients with bladder cancer

Cited by 26 publications

References 18 publications

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Chemokines in tumor proximal fluids

A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer

Contact Info

Product

Resources

About